Literature DB >> 17202119

Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

Olivier Mir, Luc Mouthon, Jérôme Alexandre, Jean-Michel Mallion, Gilbert Deray, Loïc Guillevin, François Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17202119     DOI： 10.1093/jnci/djk011

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  15 in total

Review 1.  Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.

Authors:  Erqi L Pollom; Lei Deng; Reetesh K Pai; J Martin Brown; Amato Giaccia; Billy W Loo; David B Shultz; Quynh Thu Le; Albert C Koong; Daniel T Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-01       Impact factor: 7.038

2.  VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.

Authors:  Stanislas Ropert; Olivier Vignaux; Olivier Mir; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-07-30       Impact factor: 3.850

3.  Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.

Authors:  Edouard Lecarpentier; Lamia Ouaffi; Olivier Mir; Paul Berveiller; Melinda Maurel; Eric Pujade-Lauraine; Jean Luc Bouillot; Nicolas Veyrie
Journal:  Invest New Drugs       Date:  2010-07-31       Impact factor: 3.850

4.  Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

Authors:  Romain Coriat; Stanislas Ropert; Olivier Mir; Bertrand Billemont; Stanislas Chaussade; Pierre-Philippe Massault; Benoit Blanchet; Olivier Vignaux; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-06-05       Impact factor: 3.850

5.  Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.

Authors:  Yoshinori Hoshino; Hirotoshi Hasegawa; Yoshiyuki Ishii; Takashi Endo; Hiroki Ochiai; Koji Okabayashi; Gou Kaneko; Shuji Mikami; Makio Mukai; Mototsugu Oya; Yuko Kitagawa
Journal:  Int J Clin Oncol       Date:  2011-09-17       Impact factor: 3.402

Review 6.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

Authors:  Emily S Robinson; Eliyahu V Khankin; S Ananth Karumanchi; Benjamin D Humphreys
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

7.  Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Authors:  Nicolas Magné; Cyrus Chargari; Antonin Levy; Jean-Baptiste Guy; Yacine Merrouche; Jean-Philippe Spano
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

8.  Intestinal perforation in gynecologic oncology: do all patients benefit from surgical management?

Authors:  Gunjal Garg; L Stewart Massad; Shabnam Pourabolghasem; Gongfu Zhou; Matthew A Powell; Premal H Thaker; Andrea R Hagemann; Ivy Wilkinson-Ryan; David G Mutch
Journal:  Gynecol Oncol       Date:  2013-03-13       Impact factor: 5.482

Review 9.  The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.

Authors:  Kai Wang; Xiao Qu; Ying Wang; Wei Dong; Hongchang Shen; Tiehong Zhang; Yang Ni; Qi Liu; Jiajun Du
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

Review 10.  Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.

Authors:  Maudy Walraven; Petronella O Witteveen; Martijn P J Lolkema; R van Hillegersberg; Emile E Voest; H M W Verheul
Journal:  Angiogenesis       Date:  2010-12-29       Impact factor: 9.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.